Could fewer shots control hives just as well? new trial aims to find out

NCT ID NCT05916937

Recruiting now Disease control Sponsor: Simon Francis Thomsen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether people with chronic spontaneous urticaria (long-term hives) who are well-controlled on omalizumab every 4 weeks can switch to every 6 weeks without losing control. Forty adults will be randomly assigned to continue standard dosing or extend their injection interval. The main goal is to see if disease control stays the same after 36 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omalizumab
What this could lead to: If successful, this could allow patients with well-controlled chronic hives to receive fewer injections while still keeping symptoms under control.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Extending the interval might lead to a return of hives in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic idiopathic urticaria Chronic Urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SPONTANEOUS URTICARIA CHRONIC URTICARIA, IDIOPATHIC

Contacts and locations

Locations

Department of Dermatology, Bispebjerg Hospital
RECRUITING

Copenhagen, Copenhagen N, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.